Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial

Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial

In December 2019 the SARS-CoV-2 virus appeared in the world, mainly presenting as an acute infection of the lower respiratory tract, namely pneumonia. Nearly 10% of all patients show significant pulmonary fibrotic changes after the infection. The aim of this study was to evaluate the effectiveness a...

Full description

Bibliographic Details
Main Authors: Katarzyna Kotfis, Igor Karolak, Kacper Lechowicz, Małgorzata Zegan-Barańska, Agnieszka Pikulska, Paulina Niedźwiedzka-Rystwej, Miłosz Kawa, Jerzy Sieńko, Aleksandra Szylińska, Magda Wiśniewska
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Pharmaceuticals
Subjects:
SARS-CoV-2
COVID-19
pulmonary fibrosis
pneumonia
acute respiratory distress syndrome
ARDS
Online Access:https://www.mdpi.com/1424-8247/15/2/200

Internet

https://www.mdpi.com/1424-8247/15/2/200

Similar Items